WO2005041765A1 - Device and method for monitoring body fluid and electrolyte disorders - Google Patents

Device and method for monitoring body fluid and electrolyte disorders Download PDF

Info

Publication number
WO2005041765A1
WO2005041765A1 PCT/US2004/036106 US2004036106W WO2005041765A1 WO 2005041765 A1 WO2005041765 A1 WO 2005041765A1 US 2004036106 W US2004036106 W US 2004036106W WO 2005041765 A1 WO2005041765 A1 WO 2005041765A1
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
water
radiation
wavelengths
metric
Prior art date
Application number
PCT/US2004/036106
Other languages
English (en)
French (fr)
Inventor
Joseph M. Schmitt
Martin Debreczeny
Original Assignee
Nellcor Puritan Bennett Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nellcor Puritan Bennett Incorporated filed Critical Nellcor Puritan Bennett Incorporated
Priority to AU2004285542A priority Critical patent/AU2004285542A1/en
Priority to JP2006538345A priority patent/JP2007509718A/ja
Priority to EP04796817A priority patent/EP1701653B1/en
Priority to DE602004031373T priority patent/DE602004031373D1/de
Priority to AT04796817T priority patent/ATE497722T1/de
Priority to CA002543063A priority patent/CA2543063A1/en
Publication of WO2005041765A1 publication Critical patent/WO2005041765A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
    • G01N21/3554—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for determining moisture content
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0048—Detecting, measuring or recording by applying mechanical forces or stimuli
    • A61B5/0053—Detecting, measuring or recording by applying mechanical forces or stimuli by applying pressure, e.g. compression, indentation, palpation, grasping, gauging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
    • G01N21/359—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/024—Detecting, measuring or recording pulse rate or heart rate
    • A61B5/02438—Detecting, measuring or recording pulse rate or heart rate with portable devices, e.g. worn by the patient
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/314—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry with comparison of measurements at specific and non-specific wavelengths
    • G01N2021/3181—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry with comparison of measurements at specific and non-specific wavelengths using LEDs

Definitions

  • the indicator-dilution technique which provides the most accurate direct measure of water in body tissues, is the present de facto standard for assessment of body fluid distribution. It is, however, an invasive technique that requires blood sampling. Additionally, a number of patents have disclosed designs of electrical impedance monitors for measurement of total body water. The electrical-impedance technique is based on measuring changes in the high-frequency (typically 10 KHz - 1 MHz) electrical impedance of a portion of the body. Mixed results have been obtained with the electrical-impedance technique in clinical studies of body fluid disturbances as reported by various investigators. The rather poor accuracy of the technique seen in many studies points to unresolved deficiencies of these designs when applied in a clinical setting.
  • Embodiments of the present invention provide devices and methods that measure body fluid-related metrics using spectrophotometry that may be used to facilitate diagnosis and therapeutic interventions aimed at restoring body fluid balance.
  • the disclosed invention facilitates rapid, non-invasive, and continuous measurement of fractional tissue water, ,,. Additional embodiments facilitate intermittent measurement off w .
  • the specifications of source-detector spacings, wavelength ranges of optical measurement, and algorithms for combining the measurements, provide highly accurate and reproducible methods for determination off w .
  • the present invention provides a device for measuring a body- tissue water content metric as a fraction of the fat-free tissue content of a patient using optical spectrophotometry.
  • the device includes a probe housing configured to be placed near a tissue location which is being monitored; light emission optics connected to the housing and configured to direct radiation at the tissue location; light detection optics connected to the housing and configured to receive radiation from the tissue location; and a processing device configured to process radiation from the light emission optics and the light detection optics to compute the metric where the metric includes a ratio of the water content of a portion of patient's tissue in relation to the lean or fat-free content of a portion of patient's tissue.
  • the present invention provides a device for measuring a body-tissue metric using optical spectrophotometry.
  • the device includes a probe housing configured to be placed near a tissue location which is being monitored; light emission optics connected to the housing and configured to direct radiation at the tissue location; light detection optics connected to the housing and configured to receive radiation from the tissue location; and a processing device configured to process radiation from the light emission optics and the light detection optics to compute the metric where the body tissue metric includes a quantified measure of a ratio of a difference between the water fraction in the blood and the water fraction in the extravascular tissue over the fractional volume concentration of hemoglobin in the blood.
  • the present invention provides a method for measuring a body- tissue water content metric in a human tissue location as a fraction of the fat-free tissue content of a patient using optical spectrophotometry.
  • the method includes placing a probe housing near the tissue location; emitting radiation at the tissue location using light emission optics that are configured to direct radiation at the tissue location.
  • the method may also include displaying the volume fraction of water on a display device.
  • the present invention provides a method for measuring a body-tissue metric in a human tissue location using optical spectrophotometry.
  • the method includes emitting and detecting radiation using light emission and detection optics.
  • the method includes processing the radiation from light emission and detection optics to compute the metric where the body fluid-related metric is related to a quantified measure of a ratio of a difference between the water fraction in the blood and the water fraction in the extravascular tissue over the fractional volume concentration of hemoglobin in the blood.
  • f v andf w EV are the fractional volume concentrations of water in blood and tissue, respectively
  • / ⁇ is the fractional volume concentration of hemoglobin in the blood
  • ( ⁇ BJR) ⁇ is the fractional change in reflectance at wavelength ⁇ , due to a blood volume change in the tissue
  • ⁇ 0 and aj are calibration coefficients.
  • the present invention provides a method for measuring a physiological parameter in a human tissue location.
  • the method includes emitting radiation at the tissue location using light emission optics and detecting radiation using light detection optics. Furthermore, the method includes processing the radiation from the light emission optics and the light detection optics and computing the physiological parameter, where the
  • the physiological parameter is a an oxygen saturation values. In another aspect, the physiological parameter is a fractional hemoglobin concentration.
  • the present invention provides a method of assessing changes in volume and osmolarity of body fluids near a tissue location.
  • the method includes emitting radiation at a tissue location using light emission optics and detecting radiation using light detection optics that are configured to receive radiation from the tissue location.
  • the method also includes processing the radiation from the light emission optics and the light detection optics; determining a water balance index using the processed radiation; determining a tissue water concentration and analyzing in combination the water balance index and the tissue water concentration to assess changes in volume and osmolarity of body fluids near the tissue location.
  • Fig. 1 is a graph showing tissue water fraction measured on the ear of a pig during an experiment using reflectance measurements at two wavelengths.
  • Fig. 2 is a graph showing an example regression for prediction of water from reflectances measured at three wavelengths.
  • Fig. 3 is a graph showing an example regression of a two-wavelength algorithm for determination of the difference between the intravascular and extravascular water fraction from pulsatile reflectances measured at two wavelengths.
  • Fig. 4 is a diagram of an intermittent-mode version of a fluid monitor.
  • Fig. 5 is a diagram of a continuous-mode version of a fluid monitor.
  • Fig. 6 is a block diagram of a handheld apparatus for noninvasive measurement and display of tissue water.
  • Fig. 7 is a bar graph of water content as a percentage of total and lean mass for men and women between the ages of 20 and 79.
  • Fig. 1 is a bar graph of water content as a percentage of total and lean mass for men and women between the ages of 20 and 79.
  • Fig. 9 is a graph of the correlation between separate fat-free or lean volume water fraction ("fj") measurements on the same patient.
  • Embodiments of the present invention overcome the problems of invasiveness, subjectivity, inaccuracy, and difficulty of interpretation for the purpose of clinical diagnosis and intervention, from which previous methods for body fluid assessment have suffered.
  • the method of diffuse reflectance near-infrared (“NIR") spectroscopy is employed to measure the fraction of water in skin.
  • An increase or decrease in the water content of the skin produces unique alterations of its NIR reflectance spectrum in three primary bands of wavelengths (950 - 1400 nm, 1500 - 1800 nm, and 2000 - 2300 nm) in which none-heme proteins (primarily collagen and elastin), lipids, hemoglobin, and water absorb.
  • the tissue water fraction,/ ⁇ defined spectroscopically as the ratio of the absorbance of water and the sum of the absorbances of water and other constituents of the tissue, can be measured accurately in the presence of nonspecific scattering variation, temperature, and other interfering variables.
  • tissue other than water
  • all of the other major tissue constituents such as non- heme protein, lipid ("fat"), and hemoglobin, are included, resulting in the computation of the total tissue water
  • certain constituents of the tissue are specifically excluded from the measured tissue water fraction. Spectroscopic methods for the removal of certain tissue constituents from the computation of tissue water fraction are disclosed, either by choosing spectral regions where the absorbance contribution due to these tissue constituents is small, or by appropriately combining spectroscopic measurements made at multiple wavelengths to cancel the absorbance contribution due to these tissue constituents.
  • the present invention targets the dermis, simultaneously avoiding shallow penetration that would be indicative only of the outer dead layer of the skin as well as avoiding deep penetration into the underlying, high fat-content layer, or even further into bone-containing layers.
  • Additional disclosures include the application of pressure at the tissue site of the optical measurement allowing various mobile constituents of the tissue to be included or excluded from the fractional water measurement.
  • the fractional water is measured before and after the application of pressure at the tissue site, allowing the mobile intravascular portion of the tissue to be included or excluded from the measurement.
  • measurements of the fractional water content in the intravascular space, f w IV , extravascular space, f w EV , and a difference between the two f w IV -f w EV is accomplished.
  • these measurements are accomplished by photoplethysmography, taking advantage of the natural arterial pulsation of blood through tissue.
  • fractional tissue water fractional tissue water
  • tissue water fraction tissue water fraction
  • water fraction water fraction
  • f w fractional tissue water
  • all have equivalent meanings and are meant as general terms that include all of the more specific measurements outlined above, including, but not limited to, total tissue water fraction (f ), lean tissue water fraction (f ), intravascular water fraction (f w IV ), and extravascular water fraction (f w EV ).
  • the apparatus and its associated measurement algorithm are designed according to the following guidelines: 1. To avoid the shunting of light through the superficial layers of the epidermis, the light source and detector in optical reflectance probe have low numerical apertures, typically less than 0.3. 2. The spacing between the source and detector in the probe is in the range of 1-5 mm to confine the light primarily to the dermis. 3. The reflectances are measured at wavelengths greater than approximately 1150 nm to reduce the influence of hemoglobin absorption. Alternatively, reflectances are measured at wavelengths as short as 950 nm, but the influence of hemoglobin absorbance is reduced by appropriately combining measurements of reflectance at multiple wavelengths. Or as a further alternative, the absorbance of hemoglobin is intentionally included in the denominator of the ratio used to compute tissue water fraction.
  • the lengths of the optical paths through the dermis at the wavelengths at which the reflectances are measured are matched as closely as possible. This matching is achieved by judicious selection of wavelength sets that have similar water absorption characteristics. Such wavelength sets may be selected from any one of the three primary wavelength bands (950-1400 nm, 1500-1800 nm, and 2000-2300 nm) discussed above. Wavelength pairs or sets are chosen from within one of these three primary bands, and not from across the bands. More particularly the wavelength pair of 1180 and 1300 nm is one such wavelength set where the lengths of the optical paths through the dermis at these wavelengths are matched as closely as possible.
  • the wavelengths at which the reflectances are measured are chosen to be either close to temperature isosbestic wavelengths in the water absorption spectrum or the reflectances are combined in a way that cancels the temperature dependencies of the individual reflectances.
  • absorption peaks of various biological tissue constituents may shift with variations in temperature.
  • wavelengths are selected at points in the absorption spectrum where no significant temperature shift occurs.
  • wavelength sets may be chosen such that any temperature shift is mathematically canceled out when optical measurements are combined to compute the value of a tissue water metric.
  • Such wavelength sets may be selected from any one of the three primary wavelength bands (950-1400 nm, 1500-1800 nm, and 2000-2300 nm) discussed above. Wavelength pairs or sets are chosen from within one of these three primary bands, and not from across the bands. More particularly the wavelength pair of 1180 and 1300 nm are one such pair of temperature isosbestic wavelengths in the water absorption spectrum. 6.
  • the reflectances measured at two or more wavelengths are combined to form either a single ratio, a sum of ratios, a ratio of ratios of the form logf ? ⁇ )/.?- ⁇ )], or a ratio of weighted sums of log[R( ⁇ )] terms, in which the numerator depends primarily on the absorbance of water and the denominator depends primarily on the sum of the volume fractions of water and other specific tissue constituents, such that the denominator is equally sensitive to a change in the concentration of any of these specific constituents and water.
  • the water fraction, f w is estimated according to Equation (3) below, based on the measurement of reflectances, R( ⁇ ) at three wavelengths and the empirically chosen calibration constants c 0 and c, :
  • Equations (3) Better absolute accuracy can be attained using Equations (3), as is attained using Equations (2), which also incorporates reflectance measurements at an additional wavelength.
  • Additional numerical simulations indicate that accurate measurement of the lean tissue water content, f , can be accomplished using Equation (3), by combining reflectance measurements at 1125, 1185, and 1250 nm.
  • An additional embodiment of the present invention is directed towards the measurement of water content as a fraction of fat-free or lean tissue content, f .
  • a tissue water monitor provides the clinician with an indication of whether the patient requires more, less, or no water to achieve a normo-hydrated state.
  • Such a measurement may be less universally applicable than clinically desired when it is determined using an instrument that reports fractional water relative to either total body weight or total tissue content, due to the high variability of fat content across the human population. Fat contains very little water, so variations in the fractional fat content of the body lead directly to variations in the fractional water content of the body.
  • Fig. 7 Values shown in Fig. 7 are computed from Tables II-III of Cohn et al., J. Lab. Clin. Med. (1985) 105(3), 305-311.
  • the measurement of// in tissue according to the embodiments of the present invention will be closely related to the whole body water content as a fraction of the fat-free-bone-free body content.
  • tissue water fraction,/, is estimated according to the following equation, based on the measurement of reflectances, R( ⁇ ) , at a plurality of wavelengths:
  • Equation (4) An obstacle to the quantification of tissue analytes is the high subject-to-subject variability of the scattering coefficient of tissue. Determination of the fractional tissue water in accordance with Equation (4) provides similar advantage as that of Equation (3) above, in that scattering variation is automatically cancelled, especially as long as the N+1 wavelengths are chosen from within the same wavelength band (950-1400 nm, 1500-1800 nm, or 2000- 2300 nm). An explanation of the manner in which Equation (4) automatically cancels scattering variations is provided below.
  • Equation (6) A review of Equation (6) shows that the scattering offset term has been cancelled, but the scattering dependent pathlength variation term, /, remains.
  • the pathlength variation term is also cancelled, as . shown in Equation (7):
  • Equation (7) depends only on the concentrations and extinction coefficients of the constituents of tissue and on the calibration coefficients ⁇ and q m .
  • Equation (4) allow a more general implementation by relaxing some of the constraints that are imposed by the use of Equation (3), above. For example:
  • Equation (3) may need to be sensitive to changes in water concentration but insensitive to changes in all other tissue constituents.
  • Equation (3) may require that the absorbance of all tissue constituents besides water (e.g. lipid, non-heme protein, hemoglobin) are nearly equal at wavelengths 1 and 2. This constraint is removed in Equation (4), where the coefficients p volunteer are chosen to cancel out absorbance by all tissue constituents other than water.
  • the denominator in Equation (3) may need to be equally sensitive to concentration changes of all tissue constituents to which the water fraction is to be normalized.
  • Equation (3) may require that the absorbance be equal at wavelengths 2 and 3 for all tissue constituents to be excluded from the water fraction normalization. This constraint is removed in Equation (4), where the coefficients, q m , can be chosen to cancel the absorbance contribution due to certain constituents, while equalizing the absorbance sensitivity to the remaining tissue constituents.
  • the coefficients, pmac, in the numerator of Equation (4) are chosen to cancel the contribution from all of the major light-absorbing constituents of tissue, except water.
  • the coefficients, q m in the denominator of Equation (4) are chosen to cancel the contribution from all tissue constituents other than water and protein.
  • the coefficients, q m are chosen to equalize the sensitivity of the denominator to changes in water and protein on a volume fractional basis. By computing the ratio of these two terms, the result is a fractional volume measurement of water concentration in lean tissue.
  • Equation (4) is accomplished by choosing the coefficients in the denominator of Equation (4), q m , so that all tissue constituents (including lipid) are equalized on a fractional volume basis.
  • Equation (4) By relaxing some of the constraints imposed by Equation (3), the use of Equation (4) can be expected to produce a more accurate prediction of fractional tissue water content, for the reasons set forth above.
  • Various wavelength combinations may be used based on the criteria disclosed above.
  • extinction coefficients of the major absorbing constituents of tissue were experimentally measured and various wavelength combinations of these were applied to a numerical model of tissue absorbance. The reproducibility of the algorithms incorporating the most promising of these wavelength combinations were then compared using real tissue data.
  • the real tissue data were collected from 37 different volunteers at a local hospital, with Institutional Review Board (IRB) approval.
  • the sensor measured reflected light from the pad of the finger, with a source-detector spacing of approximately 2.5 mm. The sensor was completely removed from the tissue between each pair of measurements.
  • One such preferred algorithm combines measurements at 4 wavelengths, namely: 1180, 1245, 1275, and 1330 nm. Using this selection of wavelengths, the measurement-to-measurement reproducibility, as shown in Fig. 9, is 0.37%, indicating high reproducibility of the tissue water measurements using the methods disclosed herein.
  • Equation (4) In addition to providing a method for measuring tissue water fraction, the method in accordance with Equation (4) above, also has general utility for the fractional quantification of analytes in tissue.
  • Equation (4) is extendible to the fractional concentration measurement of any tissue constituent or combination of constituents in tissue with respect to any other constituent or combination of constituents. For example, this equation is also applicable for the determination of the fractional hemoglobin content in tissue.
  • the fractional volume of total hemoglobin in tissue is determined using Equation (4) by combining reflectance measurements at wavelengths where hemoglobin is strongly absorbing with reflectance measurements where the remaining tissue constituents (such as water, lipid, and non-protein) are strongly absorbing.
  • the coefficients, ⁇ , in the numerator of Equation (4) are chosen to cancel the absorbance contributions from all tissue constituents except total hemoglobin.
  • the coeffients, q m , in the denominator of Equation (4) are chose to equalize the absorbance contributions of all major tissue constituents, on a volume fractional basis.
  • One specific wavelength combination for accomplishing this measurement is 805 nm, 1185 nm, and 1310 nm.
  • the absorbance by the oxy- and deoxyhemoglobin are approximately equal.
  • the absorbance of water, non-heme protein, and lipid are nearly equal on a fractional volume basis.
  • the tissue absorbance will be dominated by water.
  • measurement of fractional concentrations of different species of hemoglobin in tissue is performed.
  • the method provides a means of measuring the fractional concentration of hemoglobin in a first set comprised of one or more species of hemoglobin with respect to the concentration of hemoglobin in a second set comprised of one or more hemoglobin species in tissue.
  • the coefficients, ⁇ , in the numerator of Equation (4) are chosen to cancel the absorbance contributions from all tissue constituents except the hemoglobin species included in set 1.
  • the coeffients, q m , in the denominator of Equation (4) are chose to equalize the absorbance contributions from all tissue constituents except the hemoglobin species included in set 2.
  • Sets 1 and 2 are subsets of hemoglobin species that are present in the body tissue or blood. For example, such hemoglobin species include oxyhemoglobin, deoxyhemoglobin, carboxyhemoglobin, methemoglobin, sulfhemoglobin and, so on. And in general, as used herein, other physiological parameters have other subsets of constituents each being capable of absorbing at different wavelengths.
  • An additional embodiment of the disclosed invention provides the ability to quantify shifts of fluid into and out of the bloodstream through a novel application of pulse spectrophotometry.
  • This additional embodiment takes advantage of the observation that pulsations caused by expansion of blood vessels in the skin as the heart beats produce changes in the reflectance at a particular wavelength that are proportional to the difference between the effective absorption of light in the blood and the surrounding interstitial tissues.
  • Numerical simulation indicate that, if wavelengths are chosen at which water absorption is sufficiently strong, the difference between the fractions of water in the blood, f v and surrounding tissue, f w EV is proportional to the ratio of the dc-normalized reflectance changes (AR/R) measured at two wavelengths, according to Equation (8) below:
  • c 0 and c are empirically determined calibration constants. This difference, integrated over time, provides a measure of the quantity of fluid that shifts into and out of the capillaries.
  • An additional embodiment of the present invention is directed towards the measurement of water balance index, Q, such that:
  • Equation (9) is the fractional volume concentration of hemoglobin in the blood, and a ⁇ j and a ⁇ are calibration coefficients.
  • Equation (9) to determine a water balance is equivalent to using Equation (8) above, where f ⁇ , IV is set equal to 1.
  • Equation (9) provides for a more accurate determination by not neglecting the influence off h IV on the derived result. The effect of this omission can be understood by allowing total hemoglobin to vary over the normal physiological range and computing the difference between the results provided by Equation (9) when//*' is fixed or allowed to vary.
  • the quantity Q, provided by Equation (9) may be combined with a separate measurement of fractional hemoglobin concentration in blood, fi, IV , (such as may be provided by standard clinical measurements of hematocrit or total hemoglobin) in order to provide a measure of the difference between the intravascular and extravascular water content, f v - f w EV .
  • the quantity Q may have clinical utility without further manipulation.
  • the embodiments of the present invention enable the provision of a clinical indication of changes in both volume and osmolarity of body fluids.
  • Table 1 lists the 6 combinations of volume and osmolarity changes in body fluids that are clinically observed (from Physiology, 2 nd Edition, Linda S. Costanzo, Williams and Wilkins, Baltimore, 1998, pg. 156), and the expected direction and magnitude of the resultant change in fractional volume of water in blood (f v ), the fractional volume of water in tissue (f w BV ), the fractional volume of hemoglobin in blood (f h V ), the numerator of Q (Q tripod), the inverse of the denominator of Q (VQ d ), the combined result (Qpremise I Qd- Q), and the fractional volume of water in lean tissue, f .
  • Figs. 4 and 5 show diagrams of two different versions of an instrument for measuring the amount of water in body tissues.
  • the simplest version of the instrument 400 shown in Fig. 4 is designed for handheld operation and functions as a spot checker. Pressing the spring-loaded probe head 410 against the skin 412 automatically activates the display of percent tissue water 414.
  • the use of the spring-loaded probe head provides the advantages of automatically activating the display device when needed and turning the device off when not in use, thereby extending device and battery life.
  • this unique use of a spring- loaded probe also provides the variable force needed to improve the reliability of measurements.
  • Percent tissue water represents the absolute percentage of water in the skin beneath the probe (typically in the range 0.6 - 0.9).
  • the force exerted by a spring or hydraulic mechanism (not shown) inside the probe head 410 is minimized, so that the fluid content of the tissue beneath the probe is not perturbed by its presence. In this manner, the tissue water fraction, including both intravascular and extravascular fluid fractions is measured.
  • the force exerted by the probe head is sufficient to push out most of the blood in the skin below the probe to allow measurement of only the extravascular fluid fraction.
  • a pressure transducer (not shown) within the probe head 410 measures the compressibility of the skin for deriving an index of the fraction of free (mobile) water.
  • the more advanced version of the fluid monitor 500 shown in Fig. 5 is designed for use as a critical-care monitor.
  • a trend display of the time-averaged difference between the intravascular fluid volume (“IFV”) and extravascular fluid volume (“EFV”) fractions e.g., IFV-EFV 514 or the quantity Q (as defined above with reference to Equation (9), updated every few seconds.
  • IBV intravascular fluid volume
  • EVF extravascular fluid volume
  • the monitor To measure the IFV-EFV difference or Q, the monitor records blood pulses in a manner similar to a pulse oximeter. Therefore, placement of the probe on the finger or other well-perfused area of the body would be required. In cases in which perfusion is too poor to obtain reliable pulse signals, the IFV-EFV or Q display would be blanked, but the tissue water fraction (f w ) would continue to be displayed. A mechanism for mechanically inducing the pulse is built into the probe to improve the reliability of the measurement of IFV-EFV or Q under weak- pulse conditions. [0060] Fig 6.
  • FIG. 600 is a block diagram of a handheld device 600 for measuring tissue water fraction, as well as shifts in water between the IFV and EFV compartments, or a measurement of Q, with a pulse inducing mechanism.
  • a handheld device 600 for measuring tissue water fraction, as well as shifts in water between the IFV and EFV compartments, or a measurement of Q, with a pulse inducing mechanism.
  • patient places his/her finger 610 in the probe housing.
  • Rotary solenoid 612 acting through linkage 614 and collar 616 induces a mechanical pulse to improve the reliability of the measurement of IFV- EFV or Q.
  • LEDs 618 emit light at selected wavelengths and photodiode 620 measure the transmitted light. Alternately, the photodiode 620 can be placed adjacent to the LEDs to allow for the measurement of the reflectance of the emitted light.
  • Preamplifier 622 magnifies the detected signal for processing by the microprocessor 624.
  • Microprocessor 624 uses algorithms described above, determines the tissue water fraction (f w ) (such as in the total tissue volume (f w ⁇ ), within the lean tissue volume (f ), and/or within the IFV (f v ) and the EFV (f w EV )), as well as shifts in water between the IFV and EFV (such as IFV-EFV or Q), and prepares this information for display on display device 626.
  • Microprocessor 624 is also programmed to handle the appropriate timing between the rotary solenoid's operation and the signal acquisition and processing.
  • a means is provided for the user to input the fractional hemoglobin concentration (f/!
  • f h IV a quantity proportional to f h IV (such as hematocrit or total hemoglobin) in order to convert Q into IFV-EFV.
  • the design of the device and the microprocessor integrates the method and apparatus for reducing the effect of noise on measuring physiological parameters as described in U.S. Pat. No. 5,853,364, assigned to Nellcor Puritan Bennett, Inc., the entire disclosure of which is hereby incorporated herein by reference. Additionally, the design of the device and the microprocessor also integrates the electronic processor as described in U.S. Pat. No. 5,348,004, assigned to Nellcor Incorporated, the entire disclosure of which is hereby incorporated herein by reference.
  • the device can be operated in either a handheld or a tabletop mode, and it can be operated intermittently or continuously.
  • individuals skilled in the art of near-infrared spectroscopy would recognize that additional terms can be added to the algorithms used herein to incorporate reflectance measurements made at additional wavelengths and thus improve accuracy further.
  • light sources or light emission optics other then LED's including and not limited to incandescent light and narrowband light sources appropriately tuned to the desired wavelengths and associated light detection optics may be placed within the probe housing which is placed near the tissue location or may be positioned within a remote unit; and which deliver light to and receive light from the probe location via optical fibers.
  • LED's including and not limited to incandescent light and narrowband light sources appropriately tuned to the desired wavelengths and associated light detection optics
  • LED's including and not limited to incandescent light and narrowband light sources appropriately tuned to the desired wavelengths and associated light detection optics may be placed within the probe housing which is placed near the tissue location or may be positioned within a remote unit; and which deliver light to and receive light from the probe location via optical fibers.
  • the specification describes embodiments functioning in a back-scattering or a reflection mode to make optical measurements of reflectances, other embodiments can be working in a forward-scattering or a transmission mode to make these measurements.
PCT/US2004/036106 2003-10-30 2004-10-28 Device and method for monitoring body fluid and electrolyte disorders WO2005041765A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2004285542A AU2004285542A1 (en) 2003-10-30 2004-10-28 Device and method for monitoring body fluid and electrolyte disorders
JP2006538345A JP2007509718A (ja) 2003-10-30 2004-10-28 体液および電解質障害をモニタリングするデバイスおよび方法
EP04796817A EP1701653B1 (en) 2003-10-30 2004-10-28 Device and method for monitoring body fluid and electrolyte disorders
DE602004031373T DE602004031373D1 (de) 2003-10-30 2004-10-28 Vorrichtung und verfahren zur überwachung von körperflüssigkeit und elektrolytenstörungen
AT04796817T ATE497722T1 (de) 2003-10-30 2004-10-28 Vorrichtung und verfahren zur überwachung von körperflüssigkeit und elektrolytenstörungen
CA002543063A CA2543063A1 (en) 2003-10-30 2004-10-28 Device and method for monitoring body fluid and electrolyte disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/699,610 2003-10-30
US10/699,610 US7239902B2 (en) 2001-03-16 2003-10-30 Device and method for monitoring body fluid and electrolyte disorders

Publications (1)

Publication Number Publication Date
WO2005041765A1 true WO2005041765A1 (en) 2005-05-12

Family

ID=34551018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/036106 WO2005041765A1 (en) 2003-10-30 2004-10-28 Device and method for monitoring body fluid and electrolyte disorders

Country Status (9)

Country Link
US (3) US7239902B2 (US20040230106A1-20041118-C00005.png)
EP (1) EP1701653B1 (US20040230106A1-20041118-C00005.png)
JP (1) JP2007509718A (US20040230106A1-20041118-C00005.png)
AT (1) ATE497722T1 (US20040230106A1-20041118-C00005.png)
AU (1) AU2004285542A1 (US20040230106A1-20041118-C00005.png)
CA (1) CA2543063A1 (US20040230106A1-20041118-C00005.png)
DE (1) DE602004031373D1 (US20040230106A1-20041118-C00005.png)
ES (1) ES2359065T3 (US20040230106A1-20041118-C00005.png)
WO (1) WO2005041765A1 (US20040230106A1-20041118-C00005.png)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007061754A1 (en) * 2005-11-18 2007-05-31 Nellcor Puritan Bennett Llc Method for evaluating extracellular water concentration in tissue
WO2007061755A3 (en) * 2005-11-18 2008-04-17 Nellcor Puritan Bennett Llc Systems and methods to assess one or more body fluid metrics
WO2008112203A1 (en) * 2007-03-09 2008-09-18 Nellcor Puritan Bennett Llc Method for identification of sensor site by local skin spectrum data
US8229529B2 (en) 2001-03-16 2012-07-24 Nellcor Puritan Bennett Llc Device and method for monitoring body fluid and electrolyte disorders
US8255025B2 (en) 2006-06-09 2012-08-28 Nellcor Puritan Bennett Llc Bronchial or tracheal tissular water content sensor and system
US8406865B2 (en) 2008-09-30 2013-03-26 Covidien Lp Bioimpedance system and sensor and technique for using the same
US8457722B2 (en) 2001-03-16 2013-06-04 Covidien Lp Device and method for monitoring body fluid and electrolyte disorders
JP2017526412A (ja) * 2014-07-22 2017-09-14 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 非干渉的な皮膚組織ハイドレーション測定デバイス及び関連方法

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018673A (en) 1996-10-10 2000-01-25 Nellcor Puritan Bennett Incorporated Motion compatible sensor for non-invasive optical blood analysis
US8932227B2 (en) 2000-07-28 2015-01-13 Lawrence A. Lynn System and method for CO2 and oximetry integration
US9468378B2 (en) 1997-01-27 2016-10-18 Lawrence A. Lynn Airway instability detection system and method
US9042952B2 (en) 1997-01-27 2015-05-26 Lawrence A. Lynn System and method for automatic detection of a plurality of SPO2 time series pattern types
US20070191697A1 (en) 2006-02-10 2007-08-16 Lynn Lawrence A System and method for SPO2 instability detection and quantification
US9521971B2 (en) 1997-07-14 2016-12-20 Lawrence A. Lynn System and method for automatic detection of a plurality of SPO2 time series pattern types
US6675031B1 (en) 1999-04-14 2004-01-06 Mallinckrodt Inc. Method and circuit for indicating quality and accuracy of physiological measurements
US9053222B2 (en) 2002-05-17 2015-06-09 Lawrence A. Lynn Patient safety processor
US20060195041A1 (en) 2002-05-17 2006-08-31 Lynn Lawrence A Centralized hospital monitoring system for automatically detecting upper airway instability and for preventing and aborting adverse drug reactions
US20090281838A1 (en) 2008-05-07 2009-11-12 Lawrence A. Lynn Medical failure pattern search engine
US6754516B2 (en) 2001-07-19 2004-06-22 Nellcor Puritan Bennett Incorporated Nuisance alarm reductions in a physiological monitor
US7006856B2 (en) 2003-01-10 2006-02-28 Nellcor Puritan Bennett Incorporated Signal quality metrics design for qualifying data for a physiological monitor
US7016715B2 (en) 2003-01-13 2006-03-21 Nellcorpuritan Bennett Incorporated Selection of preset filter parameters based on signal quality
US7190985B2 (en) 2004-02-25 2007-03-13 Nellcor Puritan Bennett Inc. Oximeter ambient light cancellation
US7120479B2 (en) 2004-02-25 2006-10-10 Nellcor Puritan Bennett Inc. Switch-mode oximeter LED drive with a single inductor
US8611977B2 (en) * 2004-03-08 2013-12-17 Covidien Lp Method and apparatus for optical detection of mixed venous and arterial blood pulsation in tissue
US7194293B2 (en) 2004-03-08 2007-03-20 Nellcor Puritan Bennett Incorporated Selection of ensemble averaging weights for a pulse oximeter based on signal quality metrics
US7534212B2 (en) 2004-03-08 2009-05-19 Nellcor Puritan Bennett Llc Pulse oximeter with alternate heart-rate determination
US7277741B2 (en) 2004-03-09 2007-10-02 Nellcor Puritan Bennett Incorporated Pulse oximetry motion artifact rejection using near infrared absorption by water
US7392075B2 (en) 2005-03-03 2008-06-24 Nellcor Puritan Bennett Incorporated Method for enhancing pulse oximetry calculations in the presence of correlated artifacts
US20070069898A1 (en) * 2005-09-28 2007-03-29 White Mark J Glove with attached security device
US7725146B2 (en) 2005-09-29 2010-05-25 Nellcor Puritan Bennett Llc System and method for pre-processing waveforms
US7725147B2 (en) 2005-09-29 2010-05-25 Nellcor Puritan Bennett Llc System and method for removing artifacts from waveforms
US20070106126A1 (en) 2005-09-30 2007-05-10 Mannheimer Paul D Patient monitoring alarm escalation system and method
US7668579B2 (en) 2006-02-10 2010-02-23 Lynn Lawrence A System and method for the detection of physiologic response to stimulation
US8702606B2 (en) 2006-03-21 2014-04-22 Covidien Lp Patient monitoring help video system and method
US8380271B2 (en) 2006-06-15 2013-02-19 Covidien Lp System and method for generating customizable audible beep tones and alarms
US20080039718A1 (en) * 2006-08-12 2008-02-14 Philometron Platform for detection of tissue structure change
US8064975B2 (en) 2006-09-20 2011-11-22 Nellcor Puritan Bennett Llc System and method for probability based determination of estimated oxygen saturation
US8180419B2 (en) * 2006-09-27 2012-05-15 Nellcor Puritan Bennett Llc Tissue hydration estimation by spectral absorption bandwidth measurement
US8696593B2 (en) 2006-09-27 2014-04-15 Covidien Lp Method and system for monitoring intracranial pressure
US7643858B2 (en) * 2006-09-28 2010-01-05 Nellcor Puritan Bennett Llc System and method for detection of brain edema using spectrophotometry
US7922665B2 (en) 2006-09-28 2011-04-12 Nellcor Puritan Bennett Llc System and method for pulse rate calculation using a scheme for alternate weighting
US8160668B2 (en) 2006-09-29 2012-04-17 Nellcor Puritan Bennett Llc Pathological condition detector using kernel methods and oximeters
US7925511B2 (en) 2006-09-29 2011-04-12 Nellcor Puritan Bennett Llc System and method for secure voice identification in a medical device
US8068891B2 (en) 2006-09-29 2011-11-29 Nellcor Puritan Bennett Llc Symmetric LED array for pulse oximetry
US7698002B2 (en) 2006-09-29 2010-04-13 Nellcor Puritan Bennett Llc Systems and methods for user interface and identification in a medical device
US8116852B2 (en) * 2006-09-29 2012-02-14 Nellcor Puritan Bennett Llc System and method for detection of skin wounds and compartment syndromes
US8175667B2 (en) * 2006-09-29 2012-05-08 Nellcor Puritan Bennett Llc Symmetric LED array for pulse oximetry
US8068890B2 (en) 2006-09-29 2011-11-29 Nellcor Puritan Bennett Llc Pulse oximetry sensor switchover
US8728059B2 (en) 2006-09-29 2014-05-20 Covidien Lp System and method for assuring validity of monitoring parameter in combination with a therapeutic device
US20080081956A1 (en) 2006-09-29 2008-04-03 Jayesh Shah System and method for integrating voice with a medical device
US7848891B2 (en) 2006-09-29 2010-12-07 Nellcor Puritan Bennett Llc Modulation ratio determination with accommodation of uncertainty
US7706896B2 (en) 2006-09-29 2010-04-27 Nellcor Puritan Bennett Llc User interface and identification in a medical device system and method
US8175665B2 (en) * 2007-03-09 2012-05-08 Nellcor Puritan Bennett Llc Method and apparatus for spectroscopic tissue analyte measurement
US8265724B2 (en) 2007-03-09 2012-09-11 Nellcor Puritan Bennett Llc Cancellation of light shunting
US8109882B2 (en) 2007-03-09 2012-02-07 Nellcor Puritan Bennett Llc System and method for venous pulsation detection using near infrared wavelengths
US20080220512A1 (en) * 2007-03-09 2008-09-11 Nellcor Puritan Bennett Llc Tunable laser-based spectroscopy system for non-invasively measuring body water content
US8357090B2 (en) * 2007-03-09 2013-01-22 Covidien Lp Method and apparatus for estimating water reserves
US8690864B2 (en) 2007-03-09 2014-04-08 Covidien Lp System and method for controlling tissue treatment
US20080221411A1 (en) * 2007-03-09 2008-09-11 Nellcor Puritan Bennett Llc System and method for tissue hydration estimation
US8280469B2 (en) 2007-03-09 2012-10-02 Nellcor Puritan Bennett Llc Method for detection of aberrant tissue spectra
EP2170160A4 (en) * 2007-05-07 2013-01-23 Cybiocare Inc NON-INVASIVE PRESSURE DIRECTION
JP4569615B2 (ja) * 2007-09-25 2010-10-27 ブラザー工業株式会社 印刷装置
US8204567B2 (en) 2007-12-13 2012-06-19 Nellcor Puritan Bennett Llc Signal demodulation
US8092993B2 (en) 2007-12-31 2012-01-10 Nellcor Puritan Bennett Llc Hydrogel thin film for use as a biosensor
US8750953B2 (en) 2008-02-19 2014-06-10 Covidien Lp Methods and systems for alerting practitioners to physiological conditions
US8275553B2 (en) 2008-02-19 2012-09-25 Nellcor Puritan Bennett Llc System and method for evaluating physiological parameter data
US8140272B2 (en) 2008-03-27 2012-03-20 Nellcor Puritan Bennett Llc System and method for unmixing spectroscopic observations with nonnegative matrix factorization
US8437822B2 (en) 2008-03-28 2013-05-07 Covidien Lp System and method for estimating blood analyte concentration
US20090247850A1 (en) * 2008-03-28 2009-10-01 Nellcor Puritan Bennett Llc Manually Powered Oximeter
US8112375B2 (en) 2008-03-31 2012-02-07 Nellcor Puritan Bennett Llc Wavelength selection and outlier detection in reduced rank linear models
US8364224B2 (en) 2008-03-31 2013-01-29 Covidien Lp System and method for facilitating sensor and monitor communication
US8292809B2 (en) 2008-03-31 2012-10-23 Nellcor Puritan Bennett Llc Detecting chemical components from spectroscopic observations
KR20100139144A (ko) * 2008-04-21 2010-12-31 카를 프레데릭 에드만 대사 에너지 모니터링 시스템
JP2010004933A (ja) * 2008-06-24 2010-01-14 Toyota Industries Corp 非侵襲的アルコールセンサ
US9895068B2 (en) 2008-06-30 2018-02-20 Covidien Lp Pulse oximeter with wait-time indication
USD626562S1 (en) 2008-06-30 2010-11-02 Nellcor Puritan Bennett Llc Triangular saturation pattern detection indicator for a patient monitor display panel
US8862194B2 (en) 2008-06-30 2014-10-14 Covidien Lp Method for improved oxygen saturation estimation in the presence of noise
USD626561S1 (en) 2008-06-30 2010-11-02 Nellcor Puritan Bennett Llc Circular satseconds indicator and triangular saturation pattern detection indicator for a patient monitor display panel
US8386000B2 (en) 2008-09-30 2013-02-26 Covidien Lp System and method for photon density wave pulse oximetry and pulse hemometry
US8433382B2 (en) 2008-09-30 2013-04-30 Covidien Lp Transmission mode photon density wave system and method
US8417309B2 (en) 2008-09-30 2013-04-09 Covidien Lp Medical sensor
US8968193B2 (en) 2008-09-30 2015-03-03 Covidien Lp System and method for enabling a research mode on physiological monitors
ES2336997B1 (es) * 2008-10-16 2011-06-13 Sabirmedical,S.L. Sistema y aparato para la medicion no invasiva de la presion arterial.
EP2348959B1 (en) 2008-10-31 2018-09-19 Covidien LP System for facilitating observation of monitored physiologic data
CA2741044A1 (en) * 2008-10-31 2010-05-06 Nellcor Puritan Bennett Llc System and method for facilitating observation of monitored physiologic data
US20100113899A1 (en) * 2008-11-06 2010-05-06 Mark Ries Robinson Alignment System for Optically Sampling a Hand
US20110257492A1 (en) * 2009-01-29 2011-10-20 Tanja Maria Greve Method for determining the state of a skin disorder using near infrared (nir) spectroscopy
US8221319B2 (en) 2009-03-25 2012-07-17 Nellcor Puritan Bennett Llc Medical device for assessing intravascular blood volume and technique for using the same
US8509869B2 (en) 2009-05-15 2013-08-13 Covidien Lp Method and apparatus for detecting and analyzing variations in a physiologic parameter
US8494786B2 (en) 2009-07-30 2013-07-23 Covidien Lp Exponential sampling of red and infrared signals
US8494606B2 (en) 2009-08-19 2013-07-23 Covidien Lp Photoplethysmography with controlled application of sensor pressure
US8788001B2 (en) 2009-09-21 2014-07-22 Covidien Lp Time-division multiplexing in a multi-wavelength photon density wave system
US8704666B2 (en) 2009-09-21 2014-04-22 Covidien Lp Medical device interface customization systems and methods
US8494604B2 (en) 2009-09-21 2013-07-23 Covidien Lp Wavelength-division multiplexing in a multi-wavelength photon density wave system
EP2480997A2 (en) * 2009-09-24 2012-08-01 Nellcor Puritan Bennett LLC Determination of a physiological parameter
US8798704B2 (en) 2009-09-24 2014-08-05 Covidien Lp Photoacoustic spectroscopy method and system to discern sepsis from shock
US8571621B2 (en) * 2009-09-24 2013-10-29 Covidien Lp Minimax filtering for pulse oximetry
US8923945B2 (en) * 2009-09-24 2014-12-30 Covidien Lp Determination of a physiological parameter
US9554739B2 (en) 2009-09-29 2017-01-31 Covidien Lp Smart cable for coupling a medical sensor to an electronic patient monitor
US8376955B2 (en) 2009-09-29 2013-02-19 Covidien Lp Spectroscopic method and system for assessing tissue temperature
US8515511B2 (en) 2009-09-29 2013-08-20 Covidien Lp Sensor with an optical coupling material to improve plethysmographic measurements and method of using the same
US8401608B2 (en) * 2009-09-30 2013-03-19 Covidien Lp Method of analyzing photon density waves in a medical monitor
US9078610B2 (en) * 2010-02-22 2015-07-14 Covidien Lp Motion energy harvesting with wireless sensors
US8391943B2 (en) 2010-03-31 2013-03-05 Covidien Lp Multi-wavelength photon density wave system using an optical switch
US8498683B2 (en) 2010-04-30 2013-07-30 Covidien LLP Method for respiration rate and blood pressure alarm management
US7884933B1 (en) 2010-05-05 2011-02-08 Revolutionary Business Concepts, Inc. Apparatus and method for determining analyte concentrations
US9380982B2 (en) 2010-07-28 2016-07-05 Covidien Lp Adaptive alarm system and method
US8930145B2 (en) 2010-07-28 2015-01-06 Covidien Lp Light focusing continuous wave photoacoustic spectroscopy and its applications to patient monitoring
US8610769B2 (en) 2011-02-28 2013-12-17 Covidien Lp Medical monitor data collection system and method
US9037204B2 (en) 2011-09-07 2015-05-19 Covidien Lp Filtered detector array for optical patient sensors
US20140171759A1 (en) * 2012-02-15 2014-06-19 Craig William WHITE Noninvasive determination of intravascular and exctravascular hydration using near infrared spectroscopy
US9833146B2 (en) 2012-04-17 2017-12-05 Covidien Lp Surgical system and method of use of the same
US9717444B2 (en) * 2012-08-02 2017-08-01 Mark Bosin Optical polarization shift measuring system
US10052064B2 (en) 2013-04-04 2018-08-21 Thermal Technologies, Inc. Edema monitor
WO2015175360A1 (en) * 2014-05-13 2015-11-19 Montefiore Medical Center Pulseless oximeter to estimate arterial oxygen saturation noninvasively in patients with weak or absent pulses
US10499838B2 (en) 2015-04-24 2019-12-10 Drexel University Non-invasive brain water monitoring device for cerebral edema and cerebral autoregulation monitoring system and method
RU2615732C1 (ru) * 2015-12-10 2017-04-07 Общество С Ограниченной Ответственностью "Хилби" Способ определения недостатка воды в организме человека
US9498134B1 (en) 2016-03-28 2016-11-22 Cephalogics, LLC Diffuse optical tomography methods and system for determining optical properties
FR3050824B1 (fr) * 2016-04-27 2023-04-28 Connected Physics Procede et appareil de mesure de la concentration en eau dans un materiau diffusant la lumiere.
RU2645943C1 (ru) * 2016-10-04 2018-02-28 Общество с ограниченной ответственностью "ТЕЛЕБИОМЕТ" Способ неинвазивного определения концентраций компонентов крови
US11452479B2 (en) * 2017-04-05 2022-09-27 The General Hospital Corporation System and method for diagnosing soft tissue conditions
CN110115588B (zh) * 2018-02-05 2022-11-01 骆建铭 以光学方法检测生理讯号获取川崎症症状的指数的方法、装置
CN112512421A (zh) 2018-04-27 2021-03-16 海德罗斯塔西斯公司 组织水合作用监测器
KR102640317B1 (ko) * 2018-08-23 2024-02-26 삼성전자주식회사 체액 측정 장치 및 방법
US11678819B2 (en) * 2019-04-24 2023-06-20 Roxanne Abul-Haj Noninvasive applied force / optical glucose concentration determination analyzer apparatus and method of use thereof
MX2023001320A (es) * 2020-08-03 2023-02-22 Siemens Healthcare Diagnostics Inc Analizador de espectroscopia de absorbancia y metodo de uso.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5146091A (en) * 1990-04-19 1992-09-08 Inomet, Inc. Body fluid constituent measurement utilizing an interference pattern
US5755672A (en) * 1995-11-30 1998-05-26 Moritex Corporation Measuring equipment of fat and water amount existing on the object
US20010020122A1 (en) * 1990-10-06 2001-09-06 Steuer Robert R. System and method for measuring blood urea nitrogen, blood osmolarity, plasma free hemoglobin and tissue water content
EP1184663A2 (en) * 2000-09-01 2002-03-06 Spectron Tech Co., Ltd. Method and apparatus for measuring skin moisture

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5725217B2 (US20040230106A1-20041118-C00005.png) * 1974-10-14 1982-05-28
SE388045B (sv) 1974-11-28 1976-09-20 Servo Med Ab Forfarande vid metning av fran en yta genom diffusion avgiven mengd av exv. vatten samt anordning for genomforande av forfarandet
DE2712521A1 (de) * 1977-03-22 1978-09-28 Wacker Chemitronic Verfahren zum aufkitten von scheiben
US4364008A (en) * 1980-10-02 1982-12-14 Jacques Steven L Focusing probe for moisture measurement device
US4711244A (en) * 1981-12-17 1987-12-08 American Cyanamid Company Digital moisture dermatometer
US4723554A (en) * 1984-04-27 1988-02-09 Massachusetts Institute Of Technology Skin pallor and blush monitor
DE3723881A1 (de) * 1987-07-18 1989-01-26 Nicolay Gmbh Verfahren zum ermitteln der sauerstoffsaettigung des blutes eines lebenden organismus und elektronische schaltung sowie vorrichtung zum durchfuehren dieses verfahrens
US4805623A (en) 1987-09-04 1989-02-21 Vander Corporation Spectrophotometric method for quantitatively determining the concentration of a dilute component in a light- or other radiation-scattering environment
US4860753A (en) * 1987-11-04 1989-08-29 The Gillette Company Monitoring apparatus
US4805365A (en) * 1987-12-10 1989-02-21 Hamilton Industries, Inc. Corner post assembly
US4883055A (en) * 1988-03-11 1989-11-28 Puritan-Bennett Corporation Artificially induced blood pulse for use with a pulse oximeter
US4850365A (en) * 1988-03-14 1989-07-25 Futrex, Inc. Near infrared apparatus and method for determining percent fat in a body
JPH06103257B2 (ja) * 1988-12-19 1994-12-14 大塚電子株式会社 光散乱を用いた物質の吸光係数測定方法および装置
US5111817A (en) * 1988-12-29 1992-05-12 Medical Physics, Inc. Noninvasive system and method for enhanced arterial oxygen saturation determination and arterial blood pressure monitoring
US5077476A (en) * 1990-06-27 1991-12-31 Futrex, Inc. Instrument for non-invasive measurement of blood glucose
US5365066A (en) * 1989-01-19 1994-11-15 Futrex, Inc. Low cost means for increasing measurement sensitivity in LED/IRED near-infrared instruments
US5086781A (en) * 1989-11-14 1992-02-11 Bookspan Mark A Bioelectric apparatus for monitoring body fluid compartments
DE3938759A1 (de) * 1989-11-23 1991-05-29 Philips Patentverwaltung Nichtinvasive oximeteranordnung
US5224478A (en) * 1989-11-25 1993-07-06 Colin Electronics Co., Ltd. Reflecting-type oxymeter probe
JPH0440940A (ja) 1990-06-07 1992-02-12 Minolta Camera Co Ltd 総ヘモグロビン濃度測定装置
US5372136A (en) * 1990-10-06 1994-12-13 Noninvasive Medical Technology Corporation System and method for noninvasive hematocrit monitoring
CA2079058A1 (en) * 1991-10-18 1993-04-19 Stanley H. Remiszewski Surgical stapling apparatus
US5277181A (en) * 1991-12-12 1994-01-11 Vivascan Corporation Noninvasive measurement of hematocrit and hemoglobin content by differential optical analysis
AU3583293A (en) 1992-01-17 1993-08-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Optical method for monitoring arterial blood hematocrit
US5337745A (en) * 1992-03-10 1994-08-16 Benaron David A Device and method for in vivo qualitative or quantative measurement of blood chromophore concentration using blood pulse spectrophotometry
US5377674A (en) * 1992-05-08 1995-01-03 Kuestner; J. Todd Method for non-invasive and in-vitro hemoglobin concentration measurement
JP3255370B2 (ja) 1992-06-03 2002-02-12 浜松ホトニクス株式会社 皮膚中の水分の存在位置検出方法及び装置
US5735284A (en) * 1992-06-24 1998-04-07 N.I. Medical Ltd. Method and system for non-invasive determination of the main cardiorespiratory parameters of the human body
US5355880A (en) * 1992-07-06 1994-10-18 Sandia Corporation Reliable noninvasive measurement of blood gases
US5424545A (en) 1992-07-15 1995-06-13 Myron J. Block Non-invasive non-spectrophotometric infrared measurement of blood analyte concentrations
US6222189B1 (en) * 1992-07-15 2001-04-24 Optix, Lp Methods of enhancing optical signals by mechanical manipulation in non-invasive testing
US5282467A (en) * 1992-08-13 1994-02-01 Duke University Non-invasive method for detecting deep venous thrombosis in the human body
US20050062609A9 (en) 1992-08-19 2005-03-24 Lynn Lawrence A. Pulse oximetry relational alarm system for early recognition of instability and catastrophic occurrences
DE4242232C2 (de) * 1992-12-15 1998-12-10 Burkhard Kuhls Vorrichtung und Verfahren zur nicht-invasiven Konzentrationsbestimmung polarisierender Stoffe im menschlichen Körper
US5348004A (en) * 1993-03-31 1994-09-20 Nellcor Incorporated Electronic processor for pulse oximeter
CA2160252C (en) 1993-04-12 2004-06-22 Robert R. Steuer System and method for noninvasive hematocrit monitoring
US6178342B1 (en) * 1993-09-09 2001-01-23 Vasamedics Surface perfusion pressure monitoring system
US5833602A (en) * 1993-09-20 1998-11-10 Osemwota; Omoigui Process of continuous noninvasive hemometry
FR2710517B1 (fr) 1993-09-27 1995-12-22 Dior Christian Parfums Procédé d'évaluation de l'état d'hydratation de la peau et appareil destiné à sa mise en Óoeuvre.
US5747789A (en) * 1993-12-01 1998-05-05 Dynamics Imaging, Inc. Method for investigation of distribution of physiological components in human body tissues and apparatus for its realization
JPH0880288A (ja) * 1994-09-14 1996-03-26 Seiko Epson Corp 生体情報計測装置および脈波計測装置
US5701902A (en) * 1994-09-14 1997-12-30 Cedars-Sinai Medical Center Spectroscopic burn injury evaluation apparatus and method
US5615689A (en) * 1994-12-12 1997-04-01 St. Luke's-Roosevelt Hospital Method of predicting body cell mass using bioimpedance analysis
DE19612425C2 (de) * 1995-03-31 2000-08-31 Nihon Kohden Corp Apparat zur Messung von Hämoglobinkonzentration
US5638816A (en) * 1995-06-07 1997-06-17 Masimo Corporation Active pulse blood constituent monitoring
US5853364A (en) * 1995-08-07 1998-12-29 Nellcor Puritan Bennett, Inc. Method and apparatus for estimating physiological parameters using model-based adaptive filtering
US6212424B1 (en) * 1998-10-29 2001-04-03 Rio Grande Medical Technologies, Inc. Apparatus and method for determination of the adequacy of dialysis by non-invasive near-infrared spectroscopy
US5827181A (en) * 1995-09-07 1998-10-27 Hewlett-Packard Co. Noninvasive blood chemistry measurement method and system
JPH09308624A (ja) * 1996-05-23 1997-12-02 Minolta Co Ltd 濃度測定装置用アタッチメントおよび濃度測定システム
JP4212007B2 (ja) * 1996-11-26 2009-01-21 パナソニック電工株式会社 血液成分濃度の分析装置
GB9702018D0 (en) 1997-01-31 1997-03-19 Univ London Determination of the ratio of optical absorbtion coefficients at different wavelengths in a scattering medium
US6149591A (en) * 1997-02-21 2000-11-21 Duke University Refractometric devices especially adapted for the in vivo detection of refractive indices of cervical mucus
US5788643A (en) * 1997-04-22 1998-08-04 Zymed Medical Instrumentation, Inc. Process for monitoring patients with chronic congestive heart failure
GB2328279B (en) * 1997-08-12 2001-10-10 Abbott Lab Optical glucose detector
US7039446B2 (en) * 2001-01-26 2006-05-02 Sensys Medical, Inc. Indirect measurement of tissue analytes through tissue properties
CA2319480C (en) 1998-02-05 2005-01-18 In-Line Diagnostics Corporation Method and apparatus for non-invasive blood constituent monitoring
US6125297A (en) * 1998-02-06 2000-09-26 The United States Of America As Represented By The United States National Aeronautics And Space Administration Body fluids monitor
JPH11244266A (ja) 1998-02-27 1999-09-14 Matsushita Electric Works Ltd 生体表層組織の分析方法及び生体表層組織の分析装置
US6412936B1 (en) * 1998-03-03 2002-07-02 Canon Kabushiki Kaisha Ink, ink set, ink cartridge, recording unit, image recording process and image recording apparatus
US6241663B1 (en) * 1998-05-18 2001-06-05 Abbott Laboratories Method for improving non-invasive determination of the concentration of analytes in a biological sample
US6280396B1 (en) * 1998-08-03 2001-08-28 American Weights And Measures Apparatus and method for measuring body composition
US6336044B1 (en) * 1998-09-11 2002-01-01 Futrex Inc. Reliable body fat measurement in self-service health parameter Measuring system
US6064898A (en) * 1998-09-21 2000-05-16 Essential Medical Devices Non-invasive blood component analyzer
DE19855521A1 (de) 1998-12-02 2000-06-08 Tracoe Medizine Ges Fuer Tubus mit abgedichteter Manschette
US6280381B1 (en) * 1999-07-22 2001-08-28 Instrumentation Metrics, Inc. Intelligent system for noninvasive blood analyte prediction
ATE343963T1 (de) * 1999-04-20 2006-11-15 Nova Technology Corp Verfahren und vorrichtung zur messung des wasseranteils in einem substrat
JP2003528645A (ja) * 1999-04-23 2003-09-30 マサチューセッツ インスティテュート オブ テクノロジー 隔離リングセンサーデザイン
DE19923658A1 (de) 1999-05-22 2000-11-23 Infralytic Gmbh Vorrichtung zum Messen des Organisationsgrades von Wasser in Säugetierkörpern
US6675029B2 (en) * 1999-07-22 2004-01-06 Sensys Medical, Inc. Apparatus and method for quantification of tissue hydration using diffuse reflectance spectroscopy
US6442408B1 (en) * 1999-07-22 2002-08-27 Instrumentation Metrics, Inc. Method for quantification of stratum corneum hydration using diffuse reflectance spectroscopy
US6475800B1 (en) * 1999-07-22 2002-11-05 Instrumentation Metrics, Inc. Intra-serum and intra-gel for modeling human skin tissue
US6512936B1 (en) 1999-07-22 2003-01-28 Sensys Medical, Inc. Multi-tier method of classifying sample spectra for non-invasive blood analyte prediction
CA2391325C (en) * 1999-07-28 2009-12-15 Visx, Inc. Hydration and topography tissue measurements for laser sculpting
EP1214577A1 (en) 1999-08-31 2002-06-19 CME Telemetrix Inc. Method for determination of analytes using nir, adjacent visible spectrum and discrete nir wavelengths
IL132027A0 (en) * 1999-09-23 2001-03-19 M B D3 Ltd System and method for detecting dehydration
US6400971B1 (en) * 1999-10-12 2002-06-04 Orsense Ltd. Optical device for non-invasive measurement of blood-related signals and a finger holder therefor
US6635491B1 (en) * 2000-07-28 2003-10-21 Abbott Labortories Method for non-invasively determining the concentration of an analyte by compensating for the effect of tissue hydration
JP3699640B2 (ja) * 2000-08-01 2005-09-28 株式会社タニタ 多周波生体インピーダンス測定による体水分量状態判定装置
US6600946B1 (en) * 2000-08-11 2003-07-29 The Boeing Company Methods and apparatus for quantifying dermal hydration
US8135448B2 (en) * 2001-03-16 2012-03-13 Nellcor Puritan Bennett Llc Systems and methods to assess one or more body fluid metrics
US7239902B2 (en) 2001-03-16 2007-07-03 Nellor Puritan Bennett Incorporated Device and method for monitoring body fluid and electrolyte disorders
US6591122B2 (en) * 2001-03-16 2003-07-08 Nellcor Puritan Bennett Incorporated Device and method for monitoring body fluid and electrolyte disorders
US6606509B2 (en) * 2001-03-16 2003-08-12 Nellcor Puritan Bennett Incorporated Method and apparatus for improving the accuracy of noninvasive hematocrit measurements
US6898451B2 (en) 2001-03-21 2005-05-24 Minformed, L.L.C. Non-invasive blood analyte measuring system and method utilizing optical absorption
US6488677B1 (en) * 2001-05-10 2002-12-03 Thermal Technologies, Inc. System for quantifying edema
AU2002355272A1 (en) 2001-07-25 2003-02-17 Argose, Inc. Adjunct quantitative system and method for non-invasive measurement of in vivo analytes
US20040147034A1 (en) * 2001-08-14 2004-07-29 Gore Jay Prabhakar Method and apparatus for measuring a substance in a biological sample
US6840904B2 (en) 2001-10-11 2005-01-11 Jason Goldberg Medical monitoring device and system
US6950699B1 (en) * 2001-12-12 2005-09-27 Brain Child Foundation Water content probe
WO2003071939A1 (en) 2002-02-22 2003-09-04 Masimo Corporation Active pulse spectraphotometry
US8996090B2 (en) 2002-06-03 2015-03-31 Exostat Medical, Inc. Noninvasive detection of a physiologic parameter within a body tissue of a patient
JP2004081427A (ja) 2002-08-26 2004-03-18 Kenji Yoshikawa 生体内水分測定装置
JP4284674B2 (ja) 2003-01-31 2009-06-24 日本光電工業株式会社 血中吸光物質濃度測定装置
US7283242B2 (en) 2003-04-11 2007-10-16 Thornton Robert L Optical spectroscopy apparatus and method for measurement of analyte concentrations or other such species in a specimen employing a semiconductor laser-pumped, small-cavity fiber laser
JP3566277B1 (ja) 2003-06-23 2004-09-15 株式会社日立製作所 血糖値測定装置
ES2436214T3 (es) 2003-09-12 2013-12-27 Or-Nim Medical Ltd. Monitorización óptica no invasiva de una región de interés
KR100624412B1 (ko) 2003-09-16 2006-09-18 삼성전자주식회사 혈중성분 측정장치 및 이를 이용한 혈중성분측정방법
JP3590047B1 (ja) 2003-09-24 2004-11-17 株式会社日立製作所 光学測定装置及びそれを用いた血糖値測定装置
US8036727B2 (en) * 2004-08-11 2011-10-11 Glt Acquisition Corp. Methods for noninvasively measuring analyte levels in a subject
US20060167350A1 (en) * 2005-01-27 2006-07-27 Monfre Stephen L Multi-tier method of developing localized calibration models for non-invasive blood analyte prediction
US8180419B2 (en) 2006-09-27 2012-05-15 Nellcor Puritan Bennett Llc Tissue hydration estimation by spectral absorption bandwidth measurement

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5146091A (en) * 1990-04-19 1992-09-08 Inomet, Inc. Body fluid constituent measurement utilizing an interference pattern
US20010020122A1 (en) * 1990-10-06 2001-09-06 Steuer Robert R. System and method for measuring blood urea nitrogen, blood osmolarity, plasma free hemoglobin and tissue water content
US5755672A (en) * 1995-11-30 1998-05-26 Moritex Corporation Measuring equipment of fat and water amount existing on the object
EP1184663A2 (en) * 2000-09-01 2002-03-06 Spectron Tech Co., Ltd. Method and apparatus for measuring skin moisture

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8229529B2 (en) 2001-03-16 2012-07-24 Nellcor Puritan Bennett Llc Device and method for monitoring body fluid and electrolyte disorders
US8457722B2 (en) 2001-03-16 2013-06-04 Covidien Lp Device and method for monitoring body fluid and electrolyte disorders
WO2007061754A1 (en) * 2005-11-18 2007-05-31 Nellcor Puritan Bennett Llc Method for evaluating extracellular water concentration in tissue
WO2007061755A3 (en) * 2005-11-18 2008-04-17 Nellcor Puritan Bennett Llc Systems and methods to assess one or more body fluid metrics
JP2009515664A (ja) * 2005-11-18 2009-04-16 ネルコー ピューリタン ベネット エルエルシー １つ以上の体液指数を査定するシステムおよび方法
EP2251674A3 (en) * 2005-11-18 2011-10-26 Nellcor Puritan Bennett LLC Method for evaluating extracellular water concentration in tissue
US8255025B2 (en) 2006-06-09 2012-08-28 Nellcor Puritan Bennett Llc Bronchial or tracheal tissular water content sensor and system
WO2008112203A1 (en) * 2007-03-09 2008-09-18 Nellcor Puritan Bennett Llc Method for identification of sensor site by local skin spectrum data
US8406865B2 (en) 2008-09-30 2013-03-26 Covidien Lp Bioimpedance system and sensor and technique for using the same
JP2017526412A (ja) * 2014-07-22 2017-09-14 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 非干渉的な皮膚組織ハイドレーション測定デバイス及び関連方法

Also Published As

Publication number Publication date
ATE497722T1 (de) 2011-02-15
US7239902B2 (en) 2007-07-03
CA2543063A1 (en) 2005-05-12
US20070129614A1 (en) 2007-06-07
US20060084864A1 (en) 2006-04-20
US20040230106A1 (en) 2004-11-18
AU2004285542A1 (en) 2005-05-12
EP1701653B1 (en) 2011-02-09
US8509866B2 (en) 2013-08-13
US8457722B2 (en) 2013-06-04
ES2359065T3 (es) 2011-05-18
JP2007509718A (ja) 2007-04-19
DE602004031373D1 (de) 2011-03-24
EP1701653A1 (en) 2006-09-20

Similar Documents

Publication Publication Date Title
EP1701653B1 (en) Device and method for monitoring body fluid and electrolyte disorders
CA2441015C (en) Device and method for monitoring body fluid and electrolyte disorders
JP4176480B2 (ja) 非侵襲性のヘマトクリット測定値の精度を改善するための方法および装置
US8135448B2 (en) Systems and methods to assess one or more body fluid metrics
DK2034893T3 (en) Measurement of tissue oxygenation
US7657292B2 (en) Method for evaluating extracellular water concentration in tissue
Soyemi et al. Measuring tissue oxygenation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2543063

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006538345

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004285542

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004285542

Country of ref document: AU

Date of ref document: 20041028

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004285542

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004796817

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004796817

Country of ref document: EP